PT - JOURNAL ARTICLE AU - Chamberlin, Keran W. AU - Yuan, Yaqun AU - Li, Chenxi AU - Luo, Zhehui AU - Reeves, Mathew AU - Kucharska-Newton, Anna AU - Pinto, Jayant M. AU - Ma, Jiantao AU - Simonsick, Eleanor M. AU - Chen, Honglei TI - Olfactory impairment and the risk of major adverse cardiovascular outcomes in older adults AID - 10.1101/2023.10.27.23297697 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.27.23297697 4099 - http://medrxiv.org/content/early/2023/10/29/2023.10.27.23297697.short 4100 - http://medrxiv.org/content/early/2023/10/29/2023.10.27.23297697.full AB - Background Olfactory impairment is common in older adults and may be associated with adverse cardiovascular health; however, empirical evidence is sparse.Objective To examine olfaction and the risk of coronary heart disease (CHD), stroke, and congestive heart failure (CHF).Methods This study included 2,537 older adults (aged 75.6±2.8 years) from the Health ABC Study with olfaction assessed by the 12-item Brief Smell Identification Test in 1999-2000, defined as poor (score ≤8), moderate (9-10), or good (11-12). The outcomes were incident CHD, stroke, and CHF.Results During up to 12-year follow-up, 353 incident CHD, 258 stroke, and 477 CHF events were identified. Olfaction was associated with incident CHF, but not with CHD or stroke. After adjusting for demographics, the cause-specific hazard ratio (HR) of CHF was 1.35 (95% confidence interval (CI): 1.08, 1.70) for moderate and 1.39 (95%CI: 1.09, 1.76) for poor olfaction. With additional adjustment for lifestyle, chronic diseases, and biomarkers of CHF, the HR was modestly attenuated to 1.32 (95%CI: 1.05, 1.66) for moderate and 1.28 (95%CI: 1.01, 1.64) for poor olfaction. These associations were robust in pre-planned subgroup analyses by age, sex, race, and prevalent CHD/stroke. However, the associations appeared to be evident among participants who reported very-good-to-excellent health (HR=1.47 (95%CI: 1.02, 2.13) for moderate and 1.76, (95%CI: 1.20, 2.57) for poor olfaction). In contrast, null association with CHF was found among those with fair-to-poor self-reported health.Conclusions In community-dwelling older adults, a single olfaction test was associated with a long-term risk for incident CHF, particularly among those reporting very-good-to-excellent health.Competing Interest StatementDr. Jayant M. Pinto is on the speaker's bureau for Sanofi and Regeneron; he also serves as a site investigator for these two companies. He has served on an advisory board for Connect Biopharma. Other co-authors have no conflicts of interest to disclose.Clinical TrialThis study is an observational study.Funding StatementThis project was supported by a grant from the National Institute on Aging (1R01AG071517). The Health ABC study was supported by the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), the Intramural Research Program of the NIA/NIH, and NIA contracts N01AG62101, N01AG62103, N01AG62106, NIA grant R01AG028050 and NINR grant R01NR012459.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project has been approved by the Michigan State University Biomedical and Health Inst. Review Board (STUDY00004489).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in this study are available from the National Institute on Aging (NIA) Health ABC Study. To access the data, investigators should submit an analytical proposal online at https://healthabc.nia.nih.gov/ancillary-biospecimen-proposals.